2 Under-the-Radar Biotech Stocks to Buy in 2023
The biotech industry tends to be highly volatile, because of the hit-and-miss nature of the products they are developing. And yet it only takes a few blockbuster products for a biotech to become an industry titan. Moderna is a recent example, having grown from a $4 billion company to a $59 billion company thanks in large part to the pandemic and the successful rollout of its coronavirus vaccine.
As investors look for the next biotech hitmaker, they might want to take a closer look at two under-the-radar biotech firms that have some outstanding products up their sleeves. One is already putting some successful products on the market, and the other has some on the way. Each has real potential to become a thriving business in the near future.
Image source: Getty Images.
Source Fool.com
